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A B S T R A C T
Type 4 phosphodiesterases (PDE4s) of the large PDE enzyme superfamily have unique specificity for cAMP and
may, therefore, be relevant for somatotroph tumorigenesis. Somatotroph adenomas typically overexpress PDEs
probably as part of a compensatory mechanism to reduce cAMP levels. The rat PDE4A5 isoform (human
homolog PDE4A4) interacts with the AIP protein, coded by a tumour suppressor gene mutated in a subgroup of
familial isolated pituitary adenomas (FIPAs). PDE4A8 is the closest related isoform of PDE4A4. We aimed to
evaluate the expression of both PDE4A4 and PDE4A8 in GH cells of AIP-mutated adenomas and compare their
expression with that in GH cells from sporadic AIP-mutation negative GH-secreting adenomas, where we had
shown previously that both PDE4A4 and PDE4A8 isoforms had been over-expressed. Confocal immuno-
fluorescence analysis showed that both PDE4A8 and PDE4A4 had lower expression in AIP-mutated somato-
tropinoma samples compared to sporadic GH-secreting tumours (P < 0.0001 for both). Based on the association
of low PDE4A4 and PDE4A8 expression with germline AIP-mutations positive samples we suggest that lack of
AIP hinders the upregulation of PDE4A8 and PDE4A4 protein seen in sporadic somatotrophinomas. These data
point to a unique disturbance of the cAMP-PDE pathway in AIP-mutation positive adenomas, which may help to
explain their well-described poor response to somatostatin analogues.
1. Introduction
Cyclic nucleotide phosphodiesterases (PDEs) comprise a large en-
zyme superfamily (PDE1 through PDE11) that breaks down the second
messengers cAMP and/or cGMP and thereby regulate signal transduc-
tion pathways (Francis et al., 2011). PDE4 enzymes are differentiated
from other members of the PDE superfamily by their specificity for
cAMP. PDE4 subtypes PDE4A, PDE4B, PDE4C and PDE4D are encoded
by four different genes and each of these genes encodes multiple iso-
forms, via isoform-specific promoters or by alternative splicing (Conti
et al., 2003; Houslay and Adams, 2003; Houslay et al., 1998). The
PDE4A4 (rat analogue: PDE4A5) isoform is expressed in a variety of
tissues, including various brain regions (Bolger et al., 1993, 1994, 1996;
McPhee et al., 2001). This isoform has a highly conserved amino-
terminal region with 88% similarity with the rat PDE4A5 amino-
terminal region (Bolger et al., 1994) and two upstream conserved re-
gions (UCR1 and UCR2) which is also present in PDE4A8 (Mackenzie
et al., 2008). The PDE4A8 isoform, expressed in the brain and skeletal
muscle, is closely related to PDE4A4, differing only in its amino-term-
inal region (Mackenzie et al., 2008) and containing the EELD motif in
the UCR2, which may be relevant to protein-protein interactions.
When compared to other PDE isoforms, human PDE4A4/A5 is un-
iquely associated with the AIP protein (aryl hydrocarbon receptor in-
teracting protein) (Bolger et al., 2003), a co-chaperone known to have
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tumour suppressor functions in the pituitary. Loss of function mutations
in AIP are typically associated with invasive, difficult to treat somato-
troph adenomas occurring in children or young adults (Beckers et al.,
2013) either in familial or simplex setting. While wild-type AIP protein
interacts in vitro with PDE4A5 (Bolger et al., 2003), mutated AIP pro-
tein loses its ability to interact with PDE4A5 (Bolger et al., 2016; Igreja
et al., 2010). It is not known how would AIP interact with the PDE4
molecules, but as a co-chaperone it might influence protein levels in the
cell.
We have recently demonstrated the expression of both PDE4A8 and
PDE4A4 in normal human pituitary tissue, and established that both of
these proteins are overexpressed in GH-, ACTH-, PRL- and FSH-positive
adenomas (Bolger et al., 2016). Here we studied PDE4A4 and PDE4A8
protein expression in GH-secreting tumours from patients carrying
germline AIP mutations. We hypothesized that lack of functional AIP
protein might alter the expression of these phosphodiesterase isoforms.
2. Materials and methods
2.1. Subjects and patients
Samples from pituitary adenomas (n=11) were obtained at trans-
sphenoidal surgery (Table 1). Patients were diagnosed on the basis of
clinical and biochemical findings of acromegaly before surgery, fol-
lowed by immunohistochemical determination confirming the GH ex-
pression: all slides utilized from GH-secreting tumours showed more
than 90% tumour tissue, as confirmed by the haematoxylin and eosin
technique. Autopsy pituitary samples (n= 3) were collected within 24-
h of death from adult patients without evidence of any endocrine ab-
normality and were taken as controls. Pituitary architecture was eval-
uated by haematoxylin and eosin and reticulin staining. Slides from
both normal pituitary tissue and GH-secreting tumours were obtained
through consecutive cuts; in some samples we had limited tissue
available. Written informed consent was obtained from all pituitary
patients, and the protocol was approved by the institutional Research
Ethics Committee.
All patients with acromegaly (Table 1) included in the study showed
clinical and biochemical signs of acromegaly and tumour samples were
positive for GH immunohistochemistry. Patients (2 males and 2 fe-
males) with AIP mutations (F269_H275dup, R304*, Q164*, and E222*)
had macroadenomas with a median age of diagnosis at 25.5 years
(range 23–32). Sporadic patients (4 males and 3 females) with soma-
totroph macroadenomas had a median age of diagnosis of 47.5 years
(range 35–70). As expected, patients harbouring AIP mutations were
characterized by early onset of disease (age of diagnosis, P < 0.01
when compared with sporadic cases). None of the patients with acro-
megaly were treated before the surgery with somatostatin analogues or
dopamine agonists.
2.2. Immunoblotting, immunofluorescent staining, and confocal microscopy
To generate specific antibodies against human PDE4A4 and
PDE4A8, COS7 cells were transfected with the plasmids containing
pcDNAN46VSV (including a fragment of a vesicular stomatitis virus
(VSV) epitope at their carboxy terminus) to express human PDE4A4, or
with pcDNA4A8VSV to express human PDE4A8, or with vector pcDNA3
(Life Technologies), as previously described (McPhee et al., 1999;
Mackenzie et al., 2008; Christian et al., 2010). Incubation with the
primary PDE4A4 and PDE4A8 (dilution 1:500) and with VSV (Sigma,
USA, Kreis, 1986) antibodies were performed for 1 h in Tris-buffered
saline with 0.1% Tween-20, followed by 2 washes in the same buffer.
Secondary antibody incubations (SC-5099, Santa Cruz Biotechnology,
USA, 1:10,000) were performed in the same buffer, followed by 2 wa-
shes in the same buffer. Signal development was performed using en-
hanced chemiluminescence (Pierce-ThermoFisher, Waltham, MA USA).
For human PDE4A4 staining we used the mouse monoclonal anti-
body 4A4-1 generated against the specific amino-terminal region of
PDE4A4 (SAERAERERQPHRPIERADA) (GenBank L20965) (Bolger
et al., 1993, 1994, 2016; Mackenzie et al., 2008). For human PDE4A8
staining we used a mouse monoclonal antibody 4E1.16, that was gen-
erated using the unique amino-terminal region of PDE4A8 sequence
GDERSRETPESDRAN (GenBank AY593872) (Bolger et al., 2016;
Mackenzie et al., 2008). All monoclonal antibodies were purified by
limiting dilution and then grown in culture. Antibodies were then
purified from culture supernatants with a protein G-affinity matrix
(Pierce-ThermoFisher), and there was no cross reactivity between the
antibodies.
Immunostaining for GH, PDE4A4 and PDE4A8 was performed as
previously described (Bolger et al., 2016), using fat tissue as negative
control. We performed confocal immunofluorescence analysis of GH-
secreting adenomas, with and without AIP mutations, and normal pi-
tuitary tissue. In brief, after deparaffinization and application of pre-
warmed retrieval solution (Dako, California, USA, 40ml of stock into
360mL water) sections were incubated in blocking solution (1% BSA
and 0.1% Tween 20) at room temperature for 1 h and then incubated
overnight at 4 °C with one of the primary antibodies. In order to co-
localize the selected proteins in somatotroph cells, goat anti-GH (L20;
1:50) from Santa Cruz, were also added to the incubation buffer. Sec-
ondary antibodies were applied for 1 h with anti-goat Alexa 546 (1:100,
Invitrogen, USA), anti-rabbit Alexa 488 (1:400, Invitrogen) or anti-
mouse DyLight 488 (Pierce-ThermoFisher), according to the primary
antibody previously used. Images were captured through confocal mi-
croscope (Leica TCS SP5), 63× objective, and 630× original magnifi-
cation).
All confocal settings were determined at the beginning of the ima-
ging session and remained unchanged. For quantitative analysis, images
were captured at eight bits and analysed in grey scale, using the pro-
tocol we have published previously (Bolger et al., 2016; Ribeiro-
Oliveira et al., 2008). Three to four images were captured randomly
from each sample and three measurements were obtained for each
image, with about 30–50 cells also chosen randomly in each analysed
sample. ImageJ (NIH, Bethesda, USA) software was used to quantify
fluorescence intensity and area intensity, as well as area of each in-
dividual cell. The background fluorescence and the energy intensity
threshold were then subtracted from the region of interest in the same
level for all examined pictures. The relative fluorescence corresponded
to the unit ‘grey level’, varying from zero (black) to 255 (white), as an
average of the area for each cell (sum of grey value of all pixels divided
by the number of pixels/area).
Table 1
Clinical characteristics of the patients included in the study.
Patient Number Sex Diagnosis Size AIP mutation Age at
diagnosis
Patient AIP_1 M Gigantism macro p.F269_H275dup 24
Patient AIP_2 F Acromegaly macro p.R304* 27
Patient AIP_3 M Acromegaly macro p.E222* 32
Patient AIP_4 F Acromegaly macro p.Q164* 23
Patient
control_1
F Acromegay macro negative 53
Patient
control_2
F Acromegaly macro negative 42
Patient
control_3
F Acromegaly macro negative 40
Patient
control_4
M Acromegaly macro negative NA
Patient
control_5
M Acromegaly macro negative 70
Patient
control_6
M Acromegaly macro negative 53
Patient
control_7
M Acromegaly macro negative 39
M.F. Bizzi et al. Molecular and Cellular Endocrinology 476 (2018) 103–109
104
(caption on next page)
M.F. Bizzi et al. Molecular and Cellular Endocrinology 476 (2018) 103–109
105
2.3. Statistical analysis
Variables were first checked for normal distribution through the
Shapiro-Wilk test. Data were tested for statistical significance with the
non-parametric Mann-Whitney test or the Kruskal-Wallis test, followed
by Dunn's multiple comparisons test using GraphPad Prism 6.0 (La
Jolla, USA). Significance was taken as P < 0.05. Data are shown as
mean ± standard error.
3. Results
3.1. The expression of PDE4A4 in GH-secreting tumours with AIP mutations
We found overexpression of PDE4A4 in the sporadic GH-secreting
tumour cells when compared to GH cells in normal pituitary
(P < 0.0001, Fig. 1), confirming results that we have seen previously
in a different set of samples (Bolger et al., 2016). On the other hand,
GH-secreting tumour cells with AIP mutations showed a significant
decrease in the expression of PDE4A4 when compared to those without
an AIP mutation (P < 0.0001, for all), with expression levels similar to
those observed in GH cells of normal pituitary.
3.2. The expression of PDE4A8 in GH-secreting tumours with AIP mutations
There was an increased expression of PDE4A8 in somatotroph tu-
mour cells from patients without AIP mutations when compared to
normal pituitary GH cells (P < 0.0001, Fig. 2), confirming results that
we have published previously (Bolger et al., 2016). However, somato-
troph adenomas from patients with AIP mutations showed a significant
decrease in the expression of PDE4A8, when compared to tumour cells
without an AIP mutation (P < 0.0001). For two of the analysed mu-
tants, the expression level of PDE4A8 was also decreased when com-
pared to normal pituitary.
3.3. PDE4A4 and PDE4A8 expressions in AIP mutation negative GH-
secreting tumours
We compared the expression of PDE4A4 to the expression of
PDE4A8 in AIP mutation negative GH-secreting tumours. We expressed
the level of these two PDE isoforms in the AIP negative tumours based
on the level seen in somatotroph cells of the normal pituitary and then
compared the relative expression of PDE4A4 to that of PDE4A8
(P < 0.0001, Fig. 3) in AIP mutation negative GH-secreting tumours.
We found a higher level of PDE4A4 expression than PDE4A8 (Fig. 3),
and also higher PDE4A4 was seen in the AIP mutation positive samples
than PDE4A8 (Figs. 1 and 2), suggesting that this isoform plays a key
role in the compensatory rise of PDEs in somatotrophinomas.
4. Discussion
Changes affecting the cAMP pathway are known to predispose to
somatotroph adenomas, as patients with somatic GNAS mutations
leading to overactive adenylyl cyclase or with germline PRKAR1A
mutations leading to disinhibited protein kinase A often develop
pituitary hyperplasia or adenoma (Hernández-Ramírez et al., 2018).
PDEs play a key role in cAMP signalling, by catalysing the breakdown
of cAMP to AMP, thus influencing downstream regulatory effectors
(Francis et al., 2011; Maurice et al., 2014). Expression of overall PDE4A
mRNA was found to be variable in somatotroph tumours previously
(Persani et al., 2001), independently of gsp mutation status, while
PDE4A subtypes were not studied at the protein level. We have recently
established that PDE4A8 and PDE4A4 are both consistently over-ex-
pressed in sporadic somatotroph adenomas (Bolger et al., 2016). In this
study, however, we have found that both isoforms are significantly
reduced in somatotrophinomas with AIP mutations. This loss of
PDE4A4 and PDE4A8 protein might be due to the loss of functional AIP
protein. As a co-chaperone, AIP may help proteins to keep their normal
protein conformation and therefore stability. Indeed, AHR, a well-
known binding partner of AIP, have reduced levels in AIP-mutated pi-
tuitary adenomas (Jaffrain-Rea et al., 2009).
The samples used in this study had either a nonsense mutation or a
segmental duplication. The nonsense mutations lead either to nonsense
mediated decay and therefore no protein at all (Q164* and E222*) or to
very rapid degradation of the shortened protein (R304*) (Hernández-
Ramírez et al., 2016) which anyway lacks part of the crucial C-terminal
alpha-helix, therefore not representing functional protein. We have
recently shown that the segmental duplication also leads to a very rapid
degradation of the protein (Salvatori et al., 2017), while the duplicated
region theoretically disrupts a protein segment important for partner
binding. Therefore all these mutations result in complete lack of AIP
function.
When samples are compared for the presence of the different
phosphodiesterases isoforms, we noted that PDE4A4 expression in-
creases more than PDE4A8 in AIP mutation negative adenomas, sug-
gesting that PDE4A4 compensatory increase is higher for this isoform.
PDE4A4/5 is known to bind to AIP, and the EEDL motif is also present
in PDE4A8, suggesting that theoretically this protein might also bind
AIP. However, no experimental data are available regarding this due to
the poor expression of PDE4A8 in in vitro experimental settings (Bolger
et al., 2016). As AIP is a co-chaperone and one of its roles is to protect
proteins from degradation, we hypothesise that lack of AIP may lead to
accelerated PDE4A4/8 degradation in AIP-mutation positive tumours.
Overactivation of the cAMP pathway is known to increase PDE le-
vels (Peverelli et al., 2014), possibly as a compensatory mechanism.
Indeed, we have observed increased PDE4A4 and PDE4A8 protein ex-
pression in sporadic adenomas both in a previous (Bolger et al., 2016)
and in the current study. However, in adenomas with AIP mutations,
the decreased expression of PDE4A4 and PDE4A8 in the mutation
samples suggests that these tumours have an altered balance of the
cAMP-PDE pathway which may play a role in the tumorigenesis. We
note that while both PDE4A4 and PDE4A8 are showing changes into the
same direction, there is absolutely no cross reactivity between these
antibodies (Bolger et al., 2016; Mackenzie et al., 2008). In addition, the
higher expression of PDE4A4 in GH-secreting adenomas without AIP
mutation compared to PDE4A8 possibly explains why the expression of
PDE4A4 in the mutants have not reached lower levels than in normal
pituitary, as observed for two mutants with PDE4A8. We see some
variability of the reduced PDE4A8 expression, probably related to the
Fig. 1. Expression of PDE4A4 in GH-secreting tumours with different AIP mutations.
(A) Immunofluorescence with the 4A4-1 antibody in fat tissue, as a negative control.
(B) Immunoblotting with the 4A4-1 antibody. COS7 cells were transfected to express human PDE4A4 (4A4) or vector (Vect). All PDE constructs also encoded a VSV
epitope at the carboxyl-terminus of the protein. LDS-PAGE and immunoblotting with an antibody against VSV, or with 4A4-1, were performed as described in the
‘Materials and methods’ section. The PDE4A4 protein migrated at 97 kDa.
(C) Double immunofluorescent staining using monoclonal 4A4-1 (green staining) and polyclonal GH antibody (red staining) in normal pituitary (representative
example from the 3 samples), in GH-secreting tumour without AIP mutation (representative example from the 7 samples), and in GH-secreting tumour samples with
AIP mutations [(F269_H275dup, R304*, E222*)]. The bar graphs below the images provide semi-quantitation of the relative fluorescence of PDE4A4 in the 3 normal
pituitaries, 7 sporadic adenomas and the 3 individual AIP mutation positive samples. Scale bar: 25 μm. All data are shown as mean ± standard error; AU, arbitrary
units; *P < 0.0001 in relation to normal GH pituitary cells, and ●P < 0.0001 in relation to non-mutated GH-secreting tumour cells. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)
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small sample size.
In vitro data using AIP overexpression in GH3 cells lead to increased
cAMP levels but this was not altered by general phosphodiesterase in-
hibitor IBMX or PDE4 inhibitor rolipram, suggesting that PDEs do not
have a role in the AIP-induced reduction of cAMP levels in this ex-
perimental setup (Formosa et al., 2013). Lack or low level of AIP leads
to reduced expression of inhibitory G protein Galpha1-2, both in vitro and
in human samples (Ritvonen et al., 2017; Tuominen et al., 2015), but it
is unclear how these data relate to the enzymatic activity of phospho-
diesterases.
This study carries some limitations. We have a small sample size for
AIP mutation positive patients due to the rarity of the disease and
scarcity of the available high-quality AIP mutant tissue blocks. We used
a different sample for PDE4A4 and PDE4A8, but as both used samples
were nonsense mutations, they should be similar in terms of disease
mechanism. However, even with small sample size we were able to see
significant changes in pituitary PDE expression as well as to show
concordance of expression whenever samples were tested for both
isoforms. Furthermore, the double immunostaining we have used in this
study is the gold standard method to co-localize protein expression in
neoplastic and normal somatotroph tissues from patient samples. In
vitro studies are needed to further investigate the suggested me-
chanism.
In conclusion, there is reduced expression of PDE4A4 and PDE4A8
in AIP-mutated pituitary adenomas compared to sporadic somato-
trophinomas which have a, probably compensatory, elevation of these
cAMP-degrading PDE isoforms. These changes could lead to upregula-
tion of the cAMP-pathway and support tumorigenesis while possibly
contributing to somatostatin receptor ligand-resistance of patients with
AIP mutations. Further studies should investigate these pathways in the
light of the data presented here.
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